AbbVie edges ahead of Bristol Myers with strong Skyrizi and Rinvoq growth, offsetting Humira declines and portfolio headwinds.

The global Botulinum Toxins Market, valued at US$8.1 billion in 2024 stood at US$8.9 billion in 2025 and is projected to ...

There’s really no such thing as a “no brainer” stock pick. I’d say that some opportunities are more compelling than others.

The author includes U.S. and Canadian names, organized by country. Each company comes with a business summary, plus a bull ...

AbbVie Inc. (NYSE:ABBV) is one of Goldman Sachs’ top healthcare stock picks. On July 10, the stock jumped 3.4% on the ...

AbbVie has entered into a $1 billion licensing agreement with IGI Therapeutics SA, for IGI's lead investigational drug for ...

A Financial District-based drug discovery company inked a $1 billion licensing agreement with pharmaceutical giant AbbVie to ...

AbbVie has agreed to buy Capstan for up to $2.1bn, expanding its pipeline with an in vivo CAR-T therapy for autoimmune diseases.

AbbVie has acquired global rights to the lead pipeline asset of Ichnos Glenmark Innovation (IGI), the cancer and autoimmune disease candidate ISB 2001, through an exclusive licensing agreement that ...

AbbVie ABBV has been expanding its oncology portfolio over the past few years. While the company was originally focused on two blood-cancer drugs — Imbruvica and Venclexta — it has since built a ...